Physician profile
Michael Cannella
NPI 1063512457
$1,397.75
in general payments reported to CMS, 2019-2025
18 companies · $53.50 in 2025
The $53.50 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $26.16 · 2021: $157 · 2022: $863 · 2023: $298 · 2025: $53.50.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $351.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $351.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $405.49 | 2021-2023 | Vraylar |
| Takeda Pharmaceuticals U.S.A., INC. | $186.32 | 2019-2023 | Trintellix |
| Neos Therapeutics, Lp | $156.41 | 2022-2023 | Adzenys Xr-Odt |
| Otsuka America Pharmaceutical, INC. | $134.04 | 2021-2023 | Rexulti |
| Alkermes, INC. | $77.67 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $60.43 | 2022-2023 | Quviviq |
| Teva Pharmaceuticals USA, INC. | $58.25 | 2022 | |
| Bausch Health US, LLC | $54.27 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $53.50 | 2025 | Cobenfy |
| Axsome Therapeutics, INC. | $42.15 | 2022-2023 | Auvelity |
| Almatica Pharma LLC | $40.64 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $29.39 | 2022-2023 | |
| Alfasigma USA, INC. | $26.81 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $18.32 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $15.66 | 2023 | Seglentis |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $14.41 | 2022 | |
| Supernus Pharmaceuticals, INC. | $12.25 | 2022 | |
| Shire North American Group INC | $11.74 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Cannella listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.